MA52868A - Nouveaux dérivés d'isoxazolyle éther en tant que gaba a alpha5 pam - Google Patents

Nouveaux dérivés d'isoxazolyle éther en tant que gaba a alpha5 pam

Info

Publication number
MA52868A
MA52868A MA052868A MA52868A MA52868A MA 52868 A MA52868 A MA 52868A MA 052868 A MA052868 A MA 052868A MA 52868 A MA52868 A MA 52868A MA 52868 A MA52868 A MA 52868A
Authority
MA
Morocco
Prior art keywords
alpha5
gaba
pam
new derivatives
isoxazolyl
Prior art date
Application number
MA052868A
Other languages
English (en)
Inventor
Giuseppe Cecere
Zbinden Katrin Groebke
Maria-Clemencia Hernandez
Henner Knust
Andreas Koblet
Morales Andres Miguel Olivares
Angélique Patiny-Adam
Emmanuel Pinard
Valerie Runtz-Schmitt
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52868A publication Critical patent/MA52868A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA052868A 2018-06-13 2019-06-11 Nouveaux dérivés d'isoxazolyle éther en tant que gaba a alpha5 pam MA52868A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18177522 2018-06-13
EP18177825 2018-06-14

Publications (1)

Publication Number Publication Date
MA52868A true MA52868A (fr) 2021-04-21

Family

ID=66776367

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052868A MA52868A (fr) 2018-06-13 2019-06-11 Nouveaux dérivés d'isoxazolyle éther en tant que gaba a alpha5 pam

Country Status (18)

Country Link
US (1) US11840528B2 (fr)
EP (1) EP3807269A1 (fr)
JP (1) JP7478676B2 (fr)
KR (1) KR20210021019A (fr)
CN (1) CN112424196A (fr)
AU (1) AU2019286312B2 (fr)
BR (1) BR112020025355A2 (fr)
CA (1) CA3102101A1 (fr)
CL (1) CL2020003214A1 (fr)
CR (1) CR20200610A (fr)
IL (1) IL279266B2 (fr)
MA (1) MA52868A (fr)
MX (1) MX2020013518A (fr)
PE (1) PE20210555A1 (fr)
PH (1) PH12020500674A1 (fr)
SG (1) SG11202012200QA (fr)
TW (1) TWI816812B (fr)
WO (1) WO2019238633A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
CN115461337A (zh) * 2020-05-13 2022-12-09 豪夫迈·罗氏有限公司 作为GABA A α5 PAM的新型三唑基衍生物
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2026009854A1 (fr) * 2024-07-01 2026-01-08 日本たばこ産業株式会社 Composé de pyridazine et son utilisation pharmaceutique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100015648A (ko) * 2007-04-18 2010-02-12 아스트라제네카 아베 양성 알로스테릭 ｇａｂａｂ 수용체 조절제 효과를 갖는 크산틴 화합물
JP5301557B2 (ja) * 2007-12-04 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
CA2724842A1 (fr) 2008-05-19 2009-11-26 Sunovion Pharmaceuticals Inc. Composes imidazo[1,2-a]pyridines
EP2427455B1 (fr) * 2009-05-05 2020-01-15 F.Hoffmann-La Roche Ag Derives d'isoxazole-pyrazole
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
CR20190268A (es) 2016-12-08 2019-07-11 Hoffmann La Roche Nuevos deribados de isoxazolil éter como pam de gaba a alfa5

Also Published As

Publication number Publication date
PE20210555A1 (es) 2021-03-17
CN112424196A (zh) 2021-02-26
US20210094945A1 (en) 2021-04-01
TWI816812B (zh) 2023-10-01
KR20210021019A (ko) 2021-02-24
SG11202012200QA (en) 2021-01-28
EP3807269A1 (fr) 2021-04-21
WO2019238633A1 (fr) 2019-12-19
CA3102101A1 (fr) 2019-12-19
IL279266B1 (en) 2023-11-01
IL279266A (en) 2021-01-31
JP2021527099A (ja) 2021-10-11
US11840528B2 (en) 2023-12-12
BR112020025355A2 (pt) 2021-03-09
IL279266B2 (en) 2024-03-01
AU2019286312B2 (en) 2023-08-17
JP7478676B2 (ja) 2024-05-07
MX2020013518A (es) 2021-02-26
CL2020003214A1 (es) 2021-05-07
TW202016106A (zh) 2020-05-01
CR20200610A (es) 2021-02-05
PH12020500674A1 (en) 2021-06-07
AU2019286312A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MA48594A (fr) Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
MA52868A (fr) Nouveaux dérivés d'isoxazolyle éther en tant que gaba a alpha5 pam
EP3739476C0 (fr) Procédé de synthèse vocale à partir de texte multilingue
DK3880670T3 (da) Forbedret syntese af nøglemellemprodukt af kras-g12c-hæmmerforbindelse
DK3883563T3 (da) Cannabinoidforbindelse af cannabidiol-typen
EP3464272A4 (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA52489A (fr) Nouveaux composés
CO2018004124A2 (es) Compuestos heterocíclicos
EP3768671A4 (fr) Dérivés d'imidazolidine-2-one substitués en tant qu'inhibiteurs de prmt5
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
EP4037676A4 (fr) Dérivés cannabinoïdes
IL283059A (en) Continuous flow synthesis of cannabidiol
EP3999490A4 (fr) Dérivés cannabinoïdes
EP3997095A4 (fr) Dérivés cannabinoïdes
EP3801536A4 (fr) Procédés pour augmenter l'exposition au plasma de sépiaptérine
EP3504185A4 (fr) Nouveaux composés de n'-hydroxycarbamimidoyl -1,2,5-oxadiazole substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
EP4073033A4 (fr) Dérivés cannabinoïdes
EP3570832A4 (fr) Nouveaux composés utiles en tant qu'inhibteurs de l'indoléamine 2,3-dioxygénase et/ou du tryptophane dioxygénase
MA54521A (fr) Dérivés d'oxopyridine substitués
IL280047A (en) Formulation of cannabinoid compounds
IL281395A (en) Use of low volume plasma exchange for treating the early and middle stages of alzheimer's disease
IL284159A (en) Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereof
EP3844636A4 (fr) Jargon sémantique
MA53430A (fr) Nouveaux composés
EP3694502A4 (fr) Nouveaux composés cyclobutylbenzene substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)